Income Statement Vector Science and Therapeutics Corp.
Stocks
PAIN
CA92244M1041
Investment Holding Companies
|
Delayed
Toronto S.E.
03:43:09 2026-10-07 pm EDT
|
5-day change | 1st Jan Change | ||
| 1.740 CAD | -0.57% |
|
-8.90% | +3,380.00% |
| Aug. 24 | Vector Science Starts Manufacturing Pharma-Grade Peptides | MT |
| Aug. 24 | Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility | CI |
| Fiscal Period: August | 2024 (USD) | 2025 (USD) |
|---|---|---|
Cost of Goods Sold, Total | - | 150K |
Gross Profit | - | -150K |
Selling General & Admin Expenses, Total | - | 307K |
Other Operating Expenses, Total | - | 307K |
Operating Income | - | -457K |
Currency Exchange Gains (Loss) | - | -14.75K |
Other Non Operating Income (Expenses) | - | -426K |
EBT, Excl. Unusual Items | - | -898K |
EBT, Incl. Unusual Items | - | -898K |
Earnings From Continuing Operations | - | -898K |
Net Income to Company | - | -898K |
Net Income - (IS) | - | -898K |
Net Income to Common Incl Extra Items | - | -898K |
Net Income to Common Excl. Extra Items | - | -898K |
Per Share Items | ||
Net EPS - Basic | - | -0.13 |
Basic EPS - Continuing Operations | - | -0.13 |
Basic Weighted Average Shares Outstanding | - | 6.95M |
Net EPS - Diluted | - | -0.13 |
Diluted EPS - Continuing Operations | - | -0.13 |
Diluted Weighted Average Shares Outstanding | - | 6.95M |
Normalized Basic EPS | - | -0.08 |
Normalized Diluted EPS | - | -0.08 |
Supplemental Items | ||
EBITA | - | -457K |
EBIT | - | -457K |
Normalized Net Income | - | -561K |
Supplemental Operating Expense Items | ||
Marketing Expenses | - | 11.64K |
Selling and Marketing Expenses | - | 11.64K |
General and Administrative Expenses | - | 295K |
Research And Development Expense From Footnotes | - | 150K |
Select your edition
All financial news and data tailored to specific country editions
